Significant Grant Award

Summary by AI BETAClose X

CRISM Therapeutics Corporation has been awarded an £896,088 non-dilutive grant from Innovate UK, representing 70% of the £1,280,125 project cost, to support Part 1 of its Phase 2 registration-grade clinical trial for irinotecan-ChemoSeed in glioblastoma patients. This funding, which is highly competitive and received a strong application score of 90.6%, will accelerate patient recruitment, provide independent validation of the company's strategy and technology, and strengthen its position for future partnerships. The 12-month project aims to generate critical safety, dosing, and early efficacy data for regulatory approval and NHS adoption, with the ChemoSeed technology also holding potential as a platform for other indications.

Disclaimer*

UK 100

Latest directors dealings